Product Description
MIRA-55 is being developed to be the first prescription drug to target the cannabinoid receptors CB1 and CB2 for neuropathic pain, anxiety and cognitive enhancements without the impurities of marijuana or its side effects such as increased appetite and paranoia. (Sourced from: https://www.mirapharmaceuticals.com/mira-55)
Mechanisms of Action: CB1 Inhibitor,CB2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MIRA Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Generalized anxiety disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|